$3.530
+0.020 (+0.57%)At close
GDRX News
GDRX Events
GoodRx Q2 Revenue $200.4M, Exceeds Consensus
Reports Q2 revenue $200.4M, consensus $193.16M. "We entered 2026 focused on scaling Pharma Direct and subscriptions, and the second quarter provided clear evidence that those investments are translating into stronger performance," said Wendy Barnes, President and Chief Executive Officer of GoodRx. "We believe this progress is accelerating our return to growth and strengthening the long-term durability of GoodRx."
Raises FY26 Adjusted EBITDA Outlook to $240M-$250M
Consensus $775.88M. Raises FY26 adjusted EBITDA view to $240M-$250M from over $235M.
GoodRx Launches GoodRx Companion Subscription at $14.99 per Month
GoodRx launched GoodRx Companion, a new $14.99-per-month subscription. "GoodRx Companion is an important step in our evolution toward building a broader subscription model built for the way consumers are navigating healthcare today," said Wendy Barnes, President and CEO of GoodRx. "As coverage becomes more complex and out-of-pocket costs continue to rise, people are looking for trusted solutions that give them greater control and clearer value. Companion meets that demand while advancing our strategy to build deeper, more recurring consumer relationships across a growing portfolio of subscription offerings. This is where we believe the market is headed, and where we believe GoodRx is uniquely positioned to lead."
GoodRx Q1 Revenue $194M Beats Expectations
Reports Q1 revenue $194M, consensus $185.12M. "We delivered a strong start to the year, with continued momentum across our strategic growth priorities," said Wendy Barnes, President and Chief Executive Officer of GoodRx. "Our results demonstrate that the strategy we laid out last quarter is working and that we are building a sustainable value proposition. We believe that momentum is driving durable growth and increasing value for consumers and our partners."
Raises FY26 Adjusted EBITDA Outlook to Over $235M
Consensus $764.78M. Raises FY26 adjusted EBITDA view to over $235M from over $230M.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.